Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization (CRO) services in support of the agency's ADAPT (Advanced Analysis for Precision Cancer Therapy) program. The ADAPT program aims to revolutionize cancer treatment by developing adaptive strategies that leverage biomarkers to target metastatic disease, initially focusing on non-small cell lung, breast, and colorectal cancers, with the ultimate goal of improving patient survival.
As tumors evolve and develop resistance, clinicians face increasing challenges in determining the next course of therapy. The ADAPT program seeks to address this challenge by integrating computational models, novel biomarkers, and a new approach clinical trial design to enable early detection of tumor changes and informed treatment adjustments. Tempus will support the program by providing access to its portfolio of AI-enabled diagnostics, including xE, xR, xF+, xM, as well its CRO, Compass, to manage the trial's operations across all participating sites. In addition, Tempus will leverage its data integration expertise to collect and harmonize the study's data on behalf of the program.
"Tempus is proud to work with ARPA-H on the ADAPT program, which is pioneering a new era of cancer care designed to adapt throughout treatment," said Eric Lefkofsky, Founder and CEO of Tempus. "With our comprehensive molecular profiling, data integration expertise, and CRO services all in one place, Tempus is uniquely positioned to advance this effort. We look forward to helping ARPA-H deliver more precise, personalized treatments that benefit each patient."
The ADAPT program's unique approach to clinical trial design aims to enable the identification of newly acquired resistant traits in tumors, prediction of the right therapies at each point in a patient's treatment course, and strategies for better long-term prognoses. Tempus is supporting ARPA-H and its collaborators to accelerate the development of personalized therapies that can dynamically respond to the evolving nature of metastatic cancer.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcome and benefits of the collaboration between Tempus and ARPA-H and its ADAPT program. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission ("SEC") as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251009053043/en/